Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Acquires Human Longevity's Oncology Division for $37M

NEW YORK - NeoGenomics announced Friday it has acquired the oncology division assets of genome sequencing company Human Longevity for $37 million.

The purchase was financed via available cash on hand.

Human Longevity's oncology division performs next-generation sequencing services for pharmaceutical customers and generated about $10 million in revenue last year. NeoGenomics said the company expects the oncology division to be slightly dilutive to 2020 adjusted earnings.

"This acquisition will expand our Pharma Services menu to include germline, whole exome and whole genome sequencing," said NeoGenomics Chairman and CEO Douglas VanOort in a statement. Next-generation sequencing has been a focus for the Fort Myers, Florida-based firm as it grows its business.

The acquisition is NeoGenomics' largest since it bought Genoptix in October 2018 for about $127 million.

In 2015, Human Longevity collaborated with Personal Genome Diagnostics to provide genomic sequencing services and access PGD's cancer genome analysis panels. It also licensed the PGDx Enterprise Solution platform, which allows laboratories to conduct their own advanced cancer genomic testing with next-generation sequencing.  

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.